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Rationale: The purpose of this study was to investigate the clinical efficacy and safety of a 
fixed-dose combination of mometasone furoate/formoterol fumarate (MF/F) administered via 
a metered-dose inhaler in subjects with moderate-to-very severe chronic obstructive pulmonary 
disease (COPD).
Methods: This multicenter, double-blind, placebo-controlled trial had a 26-week treatment 
period and a 26-week safety extension. Subjects (n = 1196), at least 40 years old, were current or 
ex-smokers randomized to twice-daily inhaled MF/F 400/10 µg, MF/F 200/10 µg, MF 400 µg, 
F 10 µg, or placebo. The trial’s co-primary endpoints were mean changes from baseline, as area 
under the curve (AUC), in forced expiratory volume (FEV
1
) over 0–12 hours (AUC
0−12 h FEV1) 
with MF/F versus MF, and in morning (AM) pre-dose (trough) FEV
1
 with MF/F versus F after 
13 weeks of treatment. Key secondary endpoints were the effects of MF/F on respiratory health 
status using the Saint George’s Respiratory Questionnaire (SGRQ), symptom-free nights, partly 
stable COPD at 26 weeks, and time to first COPD exacerbation.
Results: The largest improvements in AUC
0−12 h FEV1 were observed with MF/F 400/10 µg and 
MF/F 200/10 µg. Serial spirometry results demonstrated that bronchodilator effects with MF/F 
occurred rapidly (within 5 minutes), persisted for 12 hours after dosing, and were sustained over 
the 26-week treatment period. Similar findings were observed for AM pre-dose FEV
1
, for which 
effects were further investigated, excluding subjects whose AM FEV
1
 data were incorrectly 
collected after 2 days from the last dose of study treatment. Improvements in SGRQ scores 
surpassed the minimum clinically important difference of more than four units with both MF/F 
treatments. At 26 weeks, no notable between-treatment differences in the occurrence and nature 
of adverse events (AEs) were reported. No unexpected AEs were observed. Overall, 90 subjects 
reported AEs considered to be treatment-related, the most common of which were lenticular 
opacities, dysphonia, and oral candidiasis.
Discussion: In conclusion, MF/F treatments improved lung function and respiratory health 
status, reduced exacerbations, and were well tolerated in subjects with moderate-to-very severe 
COPD.
Keywords: COPD, FEV
1
, spirometry, exacerbation, inhaled corticosteroid, bronchodilator
Introduction
Chronic obstructive pulmonary disease (COPD) is common in adults, with COPD 
of at least moderate severity affecting an estimated 10% of the world’s population.1 
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COPD is the third leading cause of death in the US, and 
is expected to be the third leading cause of death world-
wide by 2020.1,2 The burden of COPD on society is large 
(US$50 billion estimated direct and indirect costs in the US 
in 2010) and growing. It also poses a tremendous burden on 
people afflicted with the disease.
COPD is characterized by a progressive decline in lung 
function and slowly progressing symptoms,3 as described in 
COPD guidelines. The Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD)4 and a joint statement of the 
American Thoracic Society (ATS) and European Respiratory 
Society (ERS)3 provide guidelines on the diagnosis and man-
agement of stable COPD. All COPD grades are associated 
with a postbronchodilator forced expiratory volume (FEV) 
to forced vital capacity (FVC) ratio #0.70, indicating that 
airway obstruction is only partially reversible. These guide-
lines define four grades of COPD that stratify severity based 
on spirometry measurement of FEV in 1 second (FEV
1
) as a 
percentage of that predicted. However, many patients with 
COPD respond significantly, albeit not fully, in response to 
a bronchodilator.5,6 Although COPD cannot be cured, it is 
not an untreatable disease.
The GOLD guidelines recommend scheduled mainte-
nance treatment with long-acting bronchodilators for patients 
with moderate COPD (FEV
1
 ,80% and $50% predicted), 
and also recommend the addition of an inhaled corticosteroid 
(ICS) to long-acting bronchodilator therapy for patients with 
severe COPD (FEV
1
 ,50% predicted) and repeated exac-
erbations.4 In 2011, an official statement of the American 
College of Physicians (ACP), American College of Chest 
Physicians (ACCP), ATS, and ERS raised the FEV
1
 thresh-
old from ,50% to ,60% predicted for the recommendation 
of adding an ICS to the bronchodilator regimen of COPD 
patients who have frequent exacerbations.7 The ACP/ACCP/
ATS/ERS guidelines also state that pharmacologic combi-
nations (eg, long-acting β
2
-agonists [LABA] and ICS) may 
be used by symptomatic patients with stable COPD and an 
FEV
1
 ,60% predicted.7
Measurement of FEV
1
 is a standard endpoint that has 
been frequently used in pivotal trials evaluating potential 
COPD treatments.8–11 Other important measures of therapeu-
tic efficacy in COPD treatment studies are patient-centered 
outcomes, such as improvement of symptoms, exercise 
tolerance, and/or quality of life. Furthermore, the ability of a 
COPD treatment(s) to reduce exacerbations, especially those 
requiring hospitalization, is another widely used endpoint to 
measure therapeutic value. It is important to note that spiro-
metric responses to treatment, such as improvement in FEV
1
, 
do not always correlate with improvements in symptoms, or 
vice versa.7 This supports a rationale for evaluating multiple 
efficacy endpoints in clinical trials of COPD treatments.
Fixed-dose ICS/LABA combination inhalers are now 
available worldwide. Three ICS/LABA combinations are 
approved for the treatment of COPD: fluticasone propionate/
salmeterol (FPS), budesonide/formoterol (BF), and beclo-
methasone dipropionate/formoterol. FPS8,9,12,13 and BF11,14 
have been shown to improve lung function and health status 
in patients with COPD. Although the existing ICS/LABA 
components and fixed-dose combinations (FDC) are simi-
lar, they are not identical (eg, differences in bronchodilator 
onset15 and ICS bioavailability16). Accordingly, a new FDC 
with a different ICS component (mometasone) may bring 
different features and possible benefits to the maintenance 
treatment of patients with COPD. Mometasone furoate 
(MF) and formoterol (F) have been investigated in multiple 
pharmacologic and clinical studies. MF is distinguished 
by its high glucocorticoid receptor affinity and potent anti-
inflammatory activity, in addition to its low systemic bio-
availability.17,18 Additionally, F is distinguished by the rapid 
onset and sustained duration of its bronchodilator effect.19 
MF administered via a dry powder inhaler (DPI) has been 
investigated in COPD.20 F-DPI has been investigated21,22 
and approved for use in COPD. Combined MF/F has been 
investigated23–26 and is approved for treatment of patients 
with asthma, but has yet to be evaluated for the maintenance 
treatment of patients with COPD.
The objective of the present study was to assess the clini-
cal efficacy and safety of two doses of MF/F metered dose 
inhaler (MDI) daily: 400/10 µg BID and 200/10 µg BID 
versus the individual components or placebo in adult subjects 
with moderate-to-very severe COPD.
Methods
Patients
Included subjects were males or females $40 years old 
with FEV
1
/FVC #0.70, with a post-bronchodilator FEV
1
 
of 25%–60% predicted. Additional inclusion criteria 
were: symptoms of COPD (eg, chronic cough and sputum 
production not attributable to another disease) for at least 
24 months prior to enrollment; current or ex-smokers 
with $10 pack/year history; no use of parenteral steroids, 
oral steroids, or antibiotics within 4 weeks prior to screening; 
and clinically acceptable laboratory tests at screening. Female 
subjects of childbearing potential were required to use a med-
ically acceptable, adequate form of birth control.  Subjects 
were excluded if they had a current diagnosis of asthma, 
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 exhibited marked bronchodilator reversibility (increase in 
FEV
1
 $400 mL) versus baseline pre- bronchodilator FEV
1
, 
had a COPD exacerbation within 4 weeks prior to randomiza-
tion, or required long-term administration of supplemental 
oxygen (.15 hours/day). Additional exclusion criteria were 
a history of: lung cancer; alpha-1-antitrypsin deficiency; 
previous lung surgery; cataract extractions in both eyes; 
glaucoma or intraocular pressure $22 mmHg in either eye; or 
the presence of clinically significant medical illness(es) that, 
in the opinion of the principal investigator, could interfere 
with the study.
Study design
This was a randomized, placebo-controlled, double-blind, 
double-dummy, multicenter study (ClinicalTrials.gov 
 identifier: NCT00383721) of MF/F 400/10 µg BID and 
MF/F 200/10 µg BID compared with MF 400 µg BID and 
F 10 µg BID in adults with moderate-to-very severe COPD. 
Total dose was delivered after two inhalations BID of the 
following actuated doses: MF/F 200/5 µg, MF/F 100/5 µg, 
MF 200 µg, F 5 µg, or placebo. The study was conducted 
from 2007 to 2010 at 164 centers in North, Central, and South 
America, Europe, Africa, and Asia. All centers conformed to 
good clinical practice and to the study protocol. All centers 
had the protocol approved by an institutional review board 
and independent ethics committee. Informed consent was 
obtained from each subject. All subjects completed a 2-week 
washout/run-in period, in which previous long-acting COPD 
treatments (LABA, ICS, LABA/ICS FDC, or long-acting 
anticholinergic [eg, tiotropium]) were discontinued and sub-
stituted with an open-label, short-acting β
2
-agonist (SABA)/
short-acting anticholinergic combination.
At baseline, subjects were randomized in a 1:1:1:1:1 ratio 
to 26 weeks of double-blind treatment with MF/F 400/10 µg 
BID, MF/F 200/10 µg BID, MF 400 µg BID, F 10 µg BID, 
or placebo. Comparisons of MF 400 µg and placebo were 
included, since the clinical effects of the MF-MDI formula-
tion used in this study have not been evaluated previously. All 
inhalers were MDIs. The active and placebo MF/F and MF 
inhalers were identical in appearance, as were the active and 
placebo F inhalers. Spacers were not used in this study.
Efficacy and safety were evaluated over 6 months in the 
active treatment and placebo groups. The placebo subjects 
were discontinued from the trial after 6 months, owing 
to concerns about placebo treatment for a longer period. 
 Seventy-five percent of subjects in each active treatment 
group were randomly selected to participate in a 26-week 
safety extension, which began after the initial 26-week 
treatment period. During the safety extension, FEV
1
, peak 
 expiratory flow (PEF), and adverse event data, as well 
as additional data (eg, patient diary, electrocardiogram, 
COPD stability score, exacerbation evaluation, treat-
ment adherence, and eye examination) were assessed to 
monitor efficacy and to assure subject safety. In addition, 
 hypothalamic-pituitary-adrenal (HPA) axis and bone mineral 
density (BMD) data were collected at selected centers at the 
end of the safety extension (week 52).
Efficacy assessments
This study was designed to evaluate the contribution of 
each component of a combination inhaler (mometasone plus 
 formoterol formulation) to COPD maintenance treatment. 
The co-primary endpoints were: 1) MF/F 400/10 µg com-
pared with MF 400 µg for FEV
1
 area under the curve from 
0 to 12 hours post-dose (AUC
0–12 h
) at the week 13 endpoint 
(last observation carried forward [LOCF]) to assess the added 
benefit of F on bronchodilation, and 2) MF/F 400/10 µg 
and MF/F 200/10 µg compared with F 10 µg for AM pre-
dose (trough) FEV
1
 at the week 13 endpoint to assess the 
added benefit of MF on trough FEV
1
. Secondary efficacy 
endpoints included assessment of changes from baseline in 
FEV
1
 AUC
0–12 h
 at day 1, weeks 1, 13, 26, and the 26-week 
endpoint (LOCF), as well as assessment of changes from 
baseline in trough FEV
1
 at each visit and at the 26-week 
endpoint. Serial spirometry tests were performed at day 1, 
as well as at weeks 1, 13, and 26, which included measuring 
the pre-dose FEV
1
 30 minutes and immediately prior to the 
AM dose, and then at 5, 15, 30 minutes, and 1, 2, 3, 4, 6, 8, 
10, 11, and 12 hours post-dose.
The key secondary efficacy endpoints evaluated for the 
26-week treatment period were respiratory health status 
scores, assessed with the St George’s Respiratory Question-
naire (SGRQ);27 COPD symptom-free nights (combined 
score of 0 upon awakening for wheezing, cough, and dif-
ficulty breathing); and, as defined below, partly stable 
COPD, and time to first mild, moderate, or severe COPD 
exacerbation. The SGRQ consists of three component scores 
(symptoms, activity, impact) and a total score, each of which 
ranges from 0–100. The better SGRQ scores have a lower 
numeric value. A four-point difference from baseline or 
placebo is considered the minimum clinically important 
difference (MCID).28,29 Partly stable COPD was defined 
as no use of oral steroid rescue medication; no AM or PM 
COPD weekly average symptom score .2 during at least 7 
of 8 weeks; no moderate or severe COPD exacerbations; no 
unscheduled visits due to COPD worsenings; and/or no study 
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discontinuation due to treatment failure or treatment-related 
adverse event (AE).
COPD exacerbations were assessed during the screening 
and treatment periods, as well as during the 26-week safety 
extension, and were categorized as mild, moderate, or severe. 
A mild exacerbation was defined as a clinically judged 
deterioration of COPD symptoms (managed with increased 
short-acting bronchodilator use: $12 inhalations/day of 
SABA/short-acting anticholinergic, or $2 nebulized treat-
ments/day of 2.5 mg SABA/short-acting anticholinergic) 
on any two consecutive days. A moderate exacerbation was 
defined as a clinically judged deterioration of COPD with an 
acute change in symptoms that required antibiotic and/or oral 
steroid treatment for lower airway disease. A severe exacer-
bation was defined as a deterioration of COPD that resulted 
in emergency treatment or hospitalization due to COPD. 
Data were analyzed for the time to first mild, moderate, or 
severe COPD exacerbation and for the time to first moderate 
or severe COPD exacerbation, excluding mild events.
Safety and e-diary assessments
Safety assessments included monitoring of treatment-
emergent AEs (ie, those that occurred during randomized 
treatment), vital signs, oropharyngeal changes, and forearm 
bruising. AEs were monitored by investigators and may have 
included the onset of new illness and the exacerbation of 
pre-existing conditions (eg, COPD). Laboratory assessments, 
electrocardiography, and ophthalmologic examinations were 
conducted at screening and at final visit. Chylack Incorpo-
rated (Duxbury, MA) provided guidance for ocular exami-
nations and online training to ophthalmologists for Lens 
Opacities Classification System III (LOCS III) certification. 
Measurements of BMD and 24-hour plasma cortisol were 
conducted at selected centers. Dual-energy X-ray absorpti-
ometry (DXA) scans of the lumbar spine, left total femur, 
and femoral neck were obtained from a subgroup of subjects 
at selected centers. CCBR-Synarc (Portland, OR) provided 
centralized analysis of the DXA scans, project management 
related to DXA, and instrument quality control.
Each patient was given an e-diary (CareFusion Germany 
234 GmbH, Höchberg, Germany) with a built-in spirometer 
to capture PEF, and a self-contained device to record infor-
mation about medication use, nocturnal awakenings, COPD 
symptoms, and stability. COPD stability was evaluated with 
5- or 6-point scale (0 = best, 4 to 5 = worst), measuring 
breathlessness, mucus production, chest tightness, cough, 
interference with personal care, and interference with outdoor 
activities. All of the scores, except coughing, were based on 
5-point scales from 0 to 4. The coughing score was based 
on a 6-point scale from 0 to 5. Investigators or designated 
personnel at each site reviewed and downloaded subjects’ 
e-diary entries.
Statistical analyses
Efficacy analyses and safety summaries were based on the 
intent-to-treat principle for all randomized subjects, with at 
least some follow-up information provided. Subjects who 
discontinued early were not replaced, and AEs occurring 
up to 30 days after study completion or discontinuation 
were reported. The target sample size was 1000 subjects 
(200 subjects per treatment group). It was predetermined that 
this sample size would be sufficient to detect a difference of 
1.2 L/hour between MF/F 400/10 µg BID and MF 400 µg 
BID (in change from baseline FEV
1
 AUC
0–12 h
) with 91% 
power and a two-sided alpha level of 5%  significance, assum-
ing a pooled standard deviation of 3.6 L/hour. A 1.2 L/hour 
AUC
0–12 h
 converts to an average difference of 100 mL in 
FEV
1
 across 12 hours. A difference of this magnitude is 
considered clinically meaningful in subjects with this severity 
of COPD. For AM pre-dose FEV
1
 at the week 13 endpoint, 
the contribution of the MF 400 µg BID component was 
expected to be 80 mL for a target treatment difference of 
160 mL between MF/F 400/10 µg BID and placebo. This 
treatment difference could be detected at 93% power with a 
two-sided alpha level of 4.9%, assuming a pooled standard 
deviation of 230 mL. The alpha level was adjusted to allow 
for a nominal penalty of 0.1%.
The first co-primary efficacy endpoint was the mean 
AUC
0–12 h
 of the change in FEV
1
 from baseline to the week 13 
endpoint, measuring the contribution of F 10 µg BID to the 
combination. This analysis compared MF/F 400/10 µg BID 
versus MF 400 µg BID, MF/F 400/10 µg BID versus placebo, 
and F 10 µg BID versus placebo. All of these comparisons 
had to be statistically significant at this dose level of MF/F 
to assess successfully the F contribution at the overall alpha 
level of 5%. The second co-primary efficacy endpoint for 
the study was AM pre-dose FEV
1
 at the week 13 endpoint, 
measuring the contribution of MF to the combination. This 
analysis compared MF/F 400/10 µg BID versus F 10 µg BID, 
MF/F 400/10 µg BID versus placebo, and MF 400 µg BID 
versus placebo. All of these comparisons had to be statisti-
cally significant at this dose level of MF/F for the study to 
be successful at an adjusted alpha level of 4.9%. The alpha 
level was adjusted for an interim analysis to allow for a 
penalty of 0.1%, preserving the overall alpha level of 5% 
for the evaluation of the MF contribution. The contribution 
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of MF to the MF/F combination was evaluated by analyzing 
results in subjects whose AM pre-dose FEV
1
 measurements 
were obtained in the protocol-defined time period, using 
values considered as actual trough FEV
1
 values. In a second 
analysis, performed post database lock, FEV
1
 evaluations 
for each subject performed $2 days after the last dose of 
treatment were excluded, and the week 13 AM pre-dose 
FEV
1
 endpoint was recalculated using the last remaining 
evaluation, as specified in the study protocol.
Responses for the above co-primary endpoints were 
analyzed using an analysis of covariance (ANCOVA), extract-
ing sources of variation due to treatment, country, smoking 
status, and baseline. Pairwise comparisons were based on 
least squares means from the model. After the significance of 
co-primary endpoint analyses was confirmed, key  secondary 
endpoints were tested sequentially in order to control the 
overall alpha level of 5%. If significance was not obtained 
at any point in this process, then all subsequent comparisons 
were considered to be descriptive. Changes from baseline 
to the 26-week endpoint in SGRQ total score and COPD 
symptom-free nights (AM symptoms) were analyzed using 
the same ANCOVA as specified for the co-primary efficacy 
variables. Baseline included AM symptoms over the last week 
before the first dose. The proportion of subjects with partly 
stable COPD at endpoint (the last 8 weeks of treatment) was 
analyzed using the Cochran–Mantel–Haenszel test, control-
ling for smoking status. The time to first mild, moderate, or 
severe COPD exacerbation and the time to first moderate or 
severe COPD exacerbation were analyzed over the 26-week 
treatment period and the 26-week safety extension using the 
log-rank test for equality of survival (Kaplan–Meier) curves. 
The effect of smoking status on the survival curves was exam-
ined for the 26-week treatment period. The data were analyzed 
using SAS® software (v 9.1; SAS Institute, Cary, NC).
Results
Subject disposition
A total of 2936 subjects were screened and 1201 were 
randomized (Figure 1). Five subjects were excluded from 
 primary efficacy and safety analyses because they were 
enrolled at multiple sites. Thus, 1196 subjects were ran-
domized for analysis, meeting the target sample size of 
Screened
(n = 2936)
Randomized
(n = 1201)
Excluded from primary efficacy
and safety analysis (n = 5) 
Randomized and analyzed for
primary efficacy and safety (n = 1196)
MF/F 400/10 µg BID
(n = 225)
MF/F 200/10 µg BID
(n = 239)
MF 400 µg BID
(n = 253)
F 10 µg BID
(n = 243)
Placebo
(n = 236)
Completed 26 weeks
(n = 190; 84%)
Completed 26 weeks
(n = 202; 85%)
Completed 26 weeks
(n = 202; 80%)
Completed 26 weeks
(n = 193; 79%)
Completed 26 weeks
(n = 169; 72%)
Discontinued/reasons
(n = 34; 15%)
AE: 11 (5%)
Treatment failure: 1 (<1%)
Lost to follow-up: 0
Reasons unrelated to
treatment: 4 (2%)
Reasons related to
treatment: 5 (2%)
Noncompliance with
protocol: 7 (3%)
Did not meet protocol
eligibility: 5 (2%)
Administrative: 1 (<1%)
Discontinued/reasons
(n = 37; 15%)
AE: 5 (2%)
Treatment failure: 3 (1%)
Lost to follow-up: 0
Reasons unrelated to
treatment: 12 (5%)
Reasons related to
treatment: 3 (1%)
Noncompliance with
protocol: 5 (2%)
Did not meet protocol
eligibility: 6 (3%)
Administrative: 3 (1%)
Discontinued/reasons
(n = 51; 20%)
AE: 7 (3%)
Treatment failure: 3 (1%)
Lost to follow-up: 2 (1%)
Reasons unrelated to
treatment: 15 (6%)
Reasons related to
treatment: 6 (2%)
Noncompliance with
protocol: 4 (2%)
Did not meet protocol
eligibility: 11 (4%)
Administrative: 3 (1%)
Discontinued/reasons
(n = 50; 21%)
AE: 14 (6%)
Treatment failure: 4 (2%)
Lost to follow-up: 1 (<1%)
Reasons unrelated to
treatment: 10 (4%)
Reasons related to
treatment: 8 (3%)
Noncompliance with
protocol: 6 (2%)
Did not meet protocol
eligibility: 4 (2%)
Administrative: 3 (1%)
Discontinued/reasons
(n = 67; 28%)
AE: 13 (6%)
Treatment failure: 8 (3%)
Lost to follow-up: 4 (2%)
Reasons unrelated to
treatment: 11 (5%)
Reasons related to
treatment: 9 (4%)
Noncompliance with
protocol: 6 (3%)
Did not meet protocol
eligibility: 13 (6%)
Administrative: 3 (1%)
Figure 1 Subject disposition.
Notes: Total doses were delivered after two inhalations BID of the following actuated doses: MF/F 200/5 µg, MF/F 100/5 µg, MF 200 µg, F 5 µg, or placebo.
Abbreviations: AE, adverse event; BID, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination formulation.
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Table 1 Subject demographics and clinical characteristics
 MF/F 400/10 μg BID 
(n = 225)
MF/F 200/10 μg BID 
(n = 239)
MF 400 μg BID 
(n = 253)
F 10 μg BID 
(n = 243)
Placebo 
(n = 236)
Males, n (%) 168 (75) 175 (73) 197 (78) 182 (75) 178 (75)
Age (years), mean ± SD 59.2 ± 9.1  60.1 ± 9.0 60.5 ± 8.5 59.7 ± 8.7 58.8 ± 9.5
Weight (kg), mean ± SD 71.97 ± 19.85 71.14 ± 17.41 73.18 ± 19.14 69.75 ± 18.89 72.14 ± 21.49
White, n (%) 156 (69) 164 (69) 177 (70) 167 (69) 155 (66)
Black or African American,  
n (%)
3 (1) 10 (4) 4 (2) 4 (2) 8 (3)
Asian, n (%) 30 (13) 29 (12) 36 (14) 36 (15) 34 (14)
Current smokers, n (%) 127 (56) 119 (50) 134 (53) 123 (51) 120 (51)
Ex-smokers, n (%) 98 (44) 120 (50) 118 (47) 120 (49) 115 (49)
Smoking history, 
pack-years, mean ± SD
54.8 ± 186.4 40.3 ± 26.2 41.1 ± 23.5 45.9 ± 79.1 43.5 ± 43.1
FEV1 reversibility,  
mean % ± SD (mL)
8.69 (102) ± 13.58 8.47 (100) ± 12.65 9.67 (121) ± 14.84 10.37 (121) ± 16.64 9.48 (113) ± 13.28
Postbronchodilator FEV1
  
% predicted, mean ± SD
38.1 ± 10.8 38.7 ± 11.6 40.2 ± 11.7 38.2 ± 12.3 38.0 ± 11.5
Abbreviations: BID, twice daily; FEV1, forced expiratory volume in 1 second; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose 
combination formulation.
1000 subjects. A total of 956 subjects (80%) completed 
the 26-week double-blind treatment period, whereas 
239  subjects (20%) discontinued from the study early. 
The two most common reasons for discontinuation were 
subjects not wanting to continue for reasons unrelated to 
assigned study treatment (n = 52) and treatment-emergent 
AEs (n = 50). In the  placebo group, 67 subjects (28%) did 
not complete the 26-week treatment period, including eight 
treatment failures and four subjects lost to follow-up. In 
the active treatment groups, 15% to 21% of subjects did 
not complete the treatment period, with lower numbers of 
treatment failures and losses to follow-up than in the placebo 
group (Figure 1).
Subject demographics and disease 
characteristics
Treatment groups were well-balanced regarding baseline 
demographic characteristics with respect to age, race, and 
sex (Table 1). Overall, 75% of subjects were males, about 
70% were white, and the mean subject age was about 
60 years. The MF/F 400/10 µg group had a higher propor-
tion of current smokers (56%) than the other treatment 
groups (range: 50%–53%), and a longer mean smoking 
history (55 pack-years) than the other treatment groups 
(range: 40–46 pack-years). Also, FEV
1
 reversibility at 
screening tended to be higher in the F 10 µg group (10.37%) 
than it was in the MF/F 400/10 µg and MF/F 200/10 µg 
groups (8.69% and 8.47%, respectively). The mean post-
bronchodilator FEV
1
 at screening in all groups was between 
38% and 40% predicted.
Co-primary efficacy variables
Treatment with MF/F resulted in significant improvements 
in FEV
1
, which demonstrated the superiority of the FDC 
versus the individual components of the combination. At 
the week 13 endpoint, a significant difference of 126 mL 
was observed in the mean change from baseline in FEV
1
 
AUC
0–12 h
 between MF/F 400/10 µg and MF 400 µg groups 
(P , 0.001). MF/F 200/10 µg also significantly improved 
FEV
1
 AUC
0–12 h
 versus MF 400 µg (86 mL difference, 
P , 0.001). A significant improvement of 74 mL was 
reported for F 10 µg compared with placebo (P = 0.004) 
(Figure 2). The effect of MF over 12 hours was evident in the 
significantly greater improvement with MF 400 µg versus 
placebo (35 mL, P = 0.038). The significant  improvement 
of FEV
1
 AUC
0–12 h
 with MF/F 400/10 µg versus F 10 µg 
(87 mL, P , 0.001) confirms the contribution of MF to 
the combination.
Serial spirometric assessment of FEV
1
 post-dose at the 
beginning (day 1) and end (week 26) of treatment identified 
the rapid onset and sustained duration of bronchodilator 
effects with MF/F (Figure 3). Significantly greater increases 
in FEV
1
 occurred with both MF/F treatments compared with 
MF at all time points, including 5 minutes after dosing, both 
on day 1 (P , 0.001) and at week 26 (P # 0.035). These 
results show the benefit of F in the combination formula-
tion. The improvements in FEV
1
 with MF/F at the end of the 
26-week treatment period demonstrated the added benefit of 
the ICS component of the combination. Compared with F 
10 µg, MF/F 400/10 µg had significantly greater increases 
in FEV
1
 at all time points at week 26 (P # 0.016), whereas 
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MF/F 200/10 µg had significantly greater increases versus F 
only at the 4- and 8-hour post-dose time points (P # 0.022) 
Furthermore, as would be expected, both MF/F treatments 
were superior to placebo (P # 0.019) at all time points 
during serial spirometry assessments throughout the entire 
treatment period.
Results with MF/F 400/10 µg and MF/F 200/10 µg versus 
F 10 µg for the change from baseline in AM pre-dose (trough) 
FEV
1
 at the week 13 endpoint indicate a contribution of MF to 
the combination (Figure 4). However, the difference between 
MF/F 400/10 µg and F 10 µg (49 mL) was marginally 
significant for the pre-specified LOCF analysis (P = 0.062). In 
analyses for observed cases (analyses based on observations 
at specified time points, as opposed to observations carried 
forward for endpoint analyses) at weeks 13 and 26, as well as 
the week 26 endpoint, statistical significance was achieved, 
with differences between MF/F 400/10 µg and F 10 µg 
of 59 mL, 101 mL, and 82 mL, respectively (P # 0.033). 
A significant mean difference of 101 mL was observed 
for MF/F 400/10 µg compared with placebo (P , 0.001). 
Similarly for MF/F 200/10 µg, a significant mean increase 
of 66 mL was observed compared with placebo (P = 0.013). 
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Figure 2 FEV1 AUC0–12 h at week 13 endpoint (LOCF).
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forward; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination formulation.
Figure 3 Serial FEV1 post-dose at day 1 (A) and week 26 (B).
Notes: Significantly greater increases in FEV1 occurred with both MF/F treatments compared with MF at all time points on day 1 (P , 0.001), as well as week 26 (P # 0.035). 
Compared with F 10 µg, MF/F 400/10 µg had significantly greater increases in FEV1 at all time points on week 26 (P # 0.016), whereas MF/F 200/10 µg had significantly greater 
increases versus F only at the 4 and 8 hour post-dose time points (P # 0.022).
Abbreviations: BID, twice daily; FEV1, forced expiratory volume in 1 second; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose 
combination formulation.
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This supports an overall benefit of both doses of MF/F for 
AM pre-dose (trough) FEV
1
, while the nominally increased 
efficacy of MF/F 400/10 µg over MF/F 200/10 µg provides 
further evidence of a dose response.
Some subjects had FEV
1
 measurements long after they 
had stopped taking the study treatment. In the second  analysis 
of AM pre-dose FEV
1
, performed after database lock and 
exclusion of these subjects, statistical significance was 
achieved for this co-primary endpoint, with a difference of 
58 mL between MF/F 400/10 µg and F 10 µg (P = 0.030), 
and a difference of 105 mL between MF/F 400/10 µg and 
placebo (P , 0.001).
The co-primary endpoints were analyzed prospectively 
in all randomized subjects, and post hoc in a subgroup of 
subjects with baseline FEV
1
 ,50% predicted. The post 
hoc analyses were performed to assess treatment effects 
in subjects with severe or very severe COPD. At the week 
13 endpoint in this subgroup, significant differences in 
mean changes from baseline in FEV
1
 AUC
0–12 h
 occurred, 
with a difference of 101 mL between MF/F 400/10 µg and 
MF 400 µg (P , 0.001), 88 mL between MF/F 200/10 µg 
and MF 400 µg (P , 0.001), and 83 mL between F 
10 µg and placebo (P = 0.001). Also at the week 13 end-
point, the mean change from baseline in AM pre-dose 
(trough) FEV
1
 was 18 mL greater with MF/F 400/10 µg 
compared with F 10 µg, although the difference was not 
significant.
Key secondary efficacy variables
Reported here are changes from baseline in the SGRQ total 
score. The mean reductions in SGRQ total score at the week 
26 endpoint in the MF/F 400/10 µg and placebo groups were 
6.04 and 2.88 points, respectively. The difference between 
these treatments (3.16) was significant (P = 0.020). Also 
at the week 26 endpoint, the MF/F 200/10 µg group had a 
mean reduction in SGRQ total score of 7.99 points, with a 
significant difference (5.11; P , 0.001) from placebo. Both 
MF/F treatments achieved improvements versus baseline, 
which surpassed the MCID threshold of greater than a 
 four-unit improvement. The changes from baseline with MF 
400 µg (5.87) and F 10 µg (4.93) also surpassed the MCID 
(Figure 5).
The proportion of COPD symptom-free nights over 
26 weeks of treatment was highest in the MF/F 200/10 µg 
group (17%) and lowest in the placebo group (12%). The 
MF/F 400/10 µg, MF 400 µg, and F 10 µg groups had pro-
portions of 13%, 16%, and 13%, respectively. Comparisons 
of these treatment differences were not statistically signifi-
cant. The proportion of subjects with partly stable COPD at 
week 26 ranged from 37.5% to 43.0% across the treatment 
groups.
The proportions of subjects who experienced mild, 
moderate, or severe COPD exacerbations across the 
26-week treatment period in the MF/F 400/10 µg, MF/F 
200/10 µg, MF 400 µg, F 10 µg, and placebo groups were 
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37.6%, 32.3%, 33.3%, 40.2%, and 45.7%, respectively. The 
proportion was significantly lower than placebo for MF/F 
400/10 µg (P , 0.027), as well as for MF/F 200/10 µg 
and MF 400 µg (P , 0.001 and P = 0.003, respectively). 
In the active treatment groups, the median time to first 
exacerbation was beyond the 26-week treatment period. 
Based on the log-rank test for equality of survival curves, 
MF/F 400/10 µg, MF/F 200/10 µg, and MF 400 µg were 
superior to placebo (P # 0.027) for all randomized subjects. 
Similar results were observed for time to first exacerbation 
in  smokers and  ex-smokers, for whom log-rank testing of 
survival curves found MF/F 400/10 µg was superior to 
placebo (P = 0.027).
The majority of first COPD exacerbations were mild 
exacerbations (283/444; 64%). Some subjects on active 
treatment who experienced a mild exacerbation continued 
in the study and experienced a moderate or severe exacer-
bation later on. Therefore, an additional analysis of time 
to first exacerbation evaluated only subjects whose first 
event was a moderate or severe exacerbation (Figure 6). 
The placebo group had the highest proportion of subjects 
reporting moderate or severe COPD exacerbations as their 
first event (24.6%). The proportions of subjects with mod-
erate or severe first exacerbations in the MF/F 400/10 µg, 
MF/F 200/10 µg, MF 400 µg, and F 10 µg groups were 
15.4%, 12.8%, 16.9%, and 18.4%, respectively. Both MF/F 
groups were superior to placebo (P # 0.006), providing 
evidence of the effectiveness of both dose levels of MF/F 
in reducing the incidence of moderate or severe COPD 
exacerbations.
Safety
Treatment-emergent adverse events
Both MF/F combination doses were well tolerated during the 
26-week treatment period. The overall incidence of treatment-
emergent AEs was similar across the treatment groups, 
ranging from 33.5% for MF/F 200/10 µg to 44.4% for MF/F 
400/10 µg (Table 2). The percentage of subjects reporting 
pneumonia (including the AE terms of  pneumonia, pneumo-
nia viral, pneumonia aspiration, and lobar  pneumonia) during 
the treatment period was 1.8% overall, and ranged from 0.8% 
to 3.1% across all treatment groups. If COPD exacerbation 
met the criteria for a  serious AE (eg, was life-threatening, 
required hospitalization, or prolonged hospitalization), it 
was recorded as an AE.  Serious AEs occurred in 96 subjects 
(8.0%) during the treatment period, with numbers ranging 
from 6.7% to 8.9% across groups. A total of 20 subjects 
(1.7%) had serious AEs considered life-threatening, with 
numbers similar across all five groups. Overall, 52 subjects 
(4.3%) discontinued from treatment due to adverse events. A 
total of 15 (1.3%) subjects died during the treatment period 
across the five groups; most cases were related to cardiopul-
monary events and all were considered unlikely to be related 
to the study drug. The most commonly reported treatment-
emergent AEs during the treatment period were headache 
(4.4% overall), nasopharyngitis (3.6% overall), upper respira-
tory tract infection (3.3% overall), COPD (3.1% overall), and 
hypertension (2.8% overall) (Table 3). During the 52-week 
study period, the incidence of treatment-emergent AEs in 
the active treatment groups ranged from 44.4% for MF/F 
200/10 µg to 51.1% for MF/F 400/10 µg (Table 2).
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Figure 5 SGRQ total score change from baseline at week 26 endpoint.
Notes: Compared with placebo, significantly greater improvements in SGRQ total scores occurred with MF/F 400/10 µg (P = 0.020) and MF 400 µg (P = 0.023), as well as 
with MF/F 200/10 µg. The difference between MF/F 200/10 µg and F 10 µg was also significant (P = 0.020) at the week 26 endpoint.
Abbreviations: BID, twice daily; SGRQ, St George’s Respiratory Questionnaire; FEV1, forced expiratory volume in 1 second; F, formoterol; MF, mometasone furoate; MF/F, 
mometasone furoate/formoterol fixed-dose combination formulation.
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Treatment-related adverse events
Overall, 90 subjects (7.5%) reported a treatment-related 
AE, the most frequent of which were lenticular opacities 
(1 subject MF/F 200/10 µg, 1 subject MF/F 400/10 µg, 
2 subjects MF 400 µg, 3 subjects F 10 µg, and 1 subject 
placebo), dysphonia (2 subjects MF/F 200/10 µg, 1 subject 
MF/F 400/10 µg, 4 subjects MF 400 µg, and 1 subject 
placebo), and oral candidiasis, including the AE terms 
of oral  candidiasis, oropharyngeal candidiasis, and oral 
 fungal  infection (1 subject MF/F 200/10 µg, 2 subjects 
MF/F 400/10 µg, 6 subjects MF 400 µg, and 1 subject 
F 10 µg).
Safety extension
During the 26-week safety extension, the AEs reported 
by $2% of subjects in the active treatment groups were 
upper respiratory tract infection, nasopharyngitis, headache, 
COPD, bronchitis, influenza, arthralgia, lenticular opacities, 
hypertension, and back pain (Table 4). During the entire study 
period (treatment period plus safety extension), 23 subjects 
(2.4%) reported pneumonia (including the AE terms of pneu-
monia, pneumonia viral, pneumonia aspiration, and lobar 
pneumonia) across the four active treatment groups. Thirteen 
of the 26 events in these 23 subjects were considered to be 
severe, and all of the events were considered to be unrelated 
to the study drug.
Systemic and ocular effects
No clinically meaningful electrocardiographic changes were 
observed during the study period, with the exception of three 
subjects (one in the MF/F 400/10 µg group, one in the MF 
400 µg group, and one in the placebo group) who had cor-
rected QT interval increases from baseline. Study treatments 
had minimal effects on the HPA axis and on BMD, as mea-
sured at selected centers over the study period. The treatment 
groups were well-balanced with regard to baseline 24-hour 
plasma cortisol (range: 188.9–215.4 µg/dL · hour), and small, 
insignificant decreases in plasma cortisol were seen across 
all active treatment groups at weeks 26 and 52. For BMD 
in the lumbar spine (LS) – the region of greatest interest – 
decreases in BMD were ,2% across all treatment groups at 
weeks 26 and 52. The greatest loss of LS-BMD was 1.2% 
in the MF 400 µg group at week 26. The MF/F 200/10 µg 
group had a slight increase in LS-BMD (0.6%) at week 26, 
which was significant compared with the MF/F 400/10 µg 
(−0.9%, P = 0.035), MF 400 µg (−1.2%, P = 0.036), and 
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Figure 6 Time to first moderate or severe exacerbation over the 26-week treatment period.
Notes: *P , 0.001 versus placebo; †P = 0.027 versus placebo; ‡P = 0.003 versus placebo.
Abbreviations: F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination formulation.
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Table 2 Summary of treatment-emergent adverse events
Number of subjects (%)
MF/F 400/10 μg BID 
(n = 225)
MF/F 200/10 μg BID 
(n = 239)
MF 400 μg BID 
(n = 253)
F 10 μg BID 
(n = 243)
 Placebo BID 
(n = 236)
Treatment period (weeks 1–26)
Any AE 100 (44.4) 80 (33.5) 94 (37.2) 93 (38.3) 95 (40.3)
Treatment-related AE 19 (8.4) 13 (5.4) 25 (9.9) 19 (7.8) 14 (5.9)
Severe or life-threatening AE 18 (8.0) 15 (6.3) 10 (4.0) 15 (6.2) 12 (5.1)
Life-threatening AE 6 (2.7) 4 (1.7) 3 (1.2) 4 (1.6) 3 (1.3)
Serious AE 19 (8.4) 16 (6.7) 21 (8.3) 19 (7.8) 21 (8.9)
Discontinuation due to AE 12 (5.3) 6 (2.5) 7 (2.8) 14 (5.8) 13 (5.5)
Death 4 (1.8) 2 (0.8) 3 (1.2) 4 (1.6) 2 (0.8)
Treatment period + safety extension (weeks 1–52)
Any AE 115 (51.1) 106 (44.4) 113 (44.7) 112 (46.1)
Treatment-related AE 22 (9.8) 19 (7.9) 32 (12.6) 20 (8.2)
Severe or life-threatening AE 23 (10.2) 19 (7.9) 20 (7.9) 19 (7.8)
Life-threatening AE 7 (3.1) 6 (2.5) 6 (2.4) 6 (2.5)
Serious AE 26 (11.6) 28 (11.7) 33 (13.0) 25 (10.3)
Discontinuation due to AE 17 (7.6) 12 (5.0) 17 (6.7) 15 (6.2)
Death 6 (2.7) 2 (0.8) 5 (2.0) 6 (2.5)
Abbreviations: AE, adverse event; BID, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination formulation.
Table 3 Treatment-emergent adverse events in $2% of subjects in any treatment group
Number of subjects (%)
MF/F 400/10 μg BID 
(n = 225)
MF/F 200/10 μg BID 
(n = 239)
MF 400 μg BID 
(n = 253)
F 10 μg BID 
(n = 243)
Placebo BID 
(n = 236)
Headache 8 (3.6) 7 (2.9) 13 (5.1) 11 (4.5) 14 (5.9)
Upper respiratory tract infection 10 (4.4) 6 (2.5) 6 (2.4) 7 (2.9) 11 (4.7)
COPD* 10 (4.4) 4 (1.7) 6 (2.4) 5 (2.1) 12 (5.1)
Nasopharyngitis 9 (4.0) 5 (2.1) 10 (4.0) 10 (4.1) 9 (3.8)
Hypertension 5 (2.2) 9 (3.8) 6 (2.4) 10 (4.1) 3 (1.3)
Influenza 3 (1.3) 8 (3.3) 6 (2.4) 3 (1.2) 5 (2.1)
Pneumonia 7 (3.1) 4 (1.7) 5 (2.0) 4 (1.6) 2 (0.8)
Bronchitis 5 (2.2) 3 (1.3) 1 (0.4) 6 (2.5) 1 (0.4)
Pyrexia 5 (2.2) 1 (0.4) 5 (2.0) 0 3 (1.3)
Back pain 3 (1.3) 3 (1.3) 4 (1.6) 5 (2.1) 5 (2.1)
Peripheral edema 2 (0.9) 2 (0.8) 1 (0.4) 5 (2.1) 1 (0.4)
Cough 1 (0.4) 4 (1.7) 5 (2.0) 2 (0.8) 1 (0.4)
Dysphonia 2 (0.9) 2 (0.8) 5 (2.0) 0 1 (0.4)
Note: *If COPD exacerbation met criteria for a severe adverse event (eg, was life-threatening, required hospitalization, or prolonged hospitalization), it was recorded as 
an adverse event.
Abbreviations: BID, twice daily; COPD, chronic obstructive pulmonary disease; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose 
combination formulation.
placebo (−0.007, P = 0.030) groups. Only six subjects had 
LS-BMD loss .6% during the study period: two subjects 
each in the MF/F 400/10 µg and MF 400 µg groups, one 
subject in the MF/F 200/10 µg group, and one subject in the 
F 10 µg group.
Ophthalmologic examinations found that between 5.0% 
(MF/F 200/10 µg) and 7.5% (MF 400 µg) of subjects had 
LOCS III increases of $1 unit over the 52-week study period. 
Four MF/F 200/10 µg subjects and two MF 400 µg subjects 
reported cataracts and were discontinued from the study, as 
per protocol. Additionally, intraocular pressure $22 mmHg 
was reported for 14 subjects at week 26, and six  subjects at 
week 52.
Discussion
Treatment for 26 weeks with MF/F 400/10 µg BID and 
200/10 µg BID significantly improved lung function and 
was well tolerated in subjects with moderate-to-very severe 
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COPD. In addition, both MF/F treatments significantly 
improved respiratory health status as measured by changes 
from baseline in SGRQ total scores. The magnitude of these 
changes for both MF/F treatments achieved the threshold 
for MCID of greater than a four unit improvement from 
baseline. Also, subjects treated with MF/F experienced sig-
nificant reductions in the incidence of moderate or severe 
COPD exacerbations over the 26-week treatment period. 
The comparatively greater efficacy of MF/F 400/10 µg over 
MF/F 200/10 µg on lung function suggests a possible dose-
response effect of the MF component in the MF/F combina-
tion formulation.
Based on 12-hour serial spirometry measurements, 
MF/F treatment showed a rapid onset of bronchodila-
tion, driven by the F component. The MF/F groups had 
increases in FEV
1
 of about 10% at 5 minutes post-dose 
on day 1, and increases .15% at 5 minutes post-dose at 
week 26. The latter result shows that the bronchodilator 
effect of F was maintained over the 26-week treatment 
period, with no evidence of tachyphylaxis. Furthermore, the 
12-hour period for serial spirometry in this study was substan-
tially longer than the 1- or 2-hour serial spirometry assess-
ments in some pivotal trials of other ICS/LABA FDCs,8,9,11 
although a recent trial of budesonide/formoterol included 
serial spirometry data that extended for 12 hours.30
Clinical trials of pharmacotherapy for COPD may 
fail to show an improvement in SGRQ that meets the 
four unit MCID for total score.11,14 In the present multi-
center trial, both MF/F groups had mean improvements 
from baseline .4 units, achieving the protocol-defined 
MCID, while differences from placebo ranged from 3.16 
to 5.11 units. The trial demonstrated a clinically relevant 
improvement in respiratory health status compared with 
placebo at week 13 and at endpoint.
The probability of a COPD exacerbation was reduced 
with both MF/F combinations. The MF/F 400/10 µg group 
had a 17.7% relative risk reduction for mild, moderate, or 
severe exacerbations, compared with placebo, whereas the 
MF/F 200/10 µg group had a 29.3% relative risk reduction 
for these COPD exacerbations. When only the more clini-
cally meaningful moderate or severe COPD exacerbations 
were analyzed, MF/F 400/10 µg showed a 37.4% relative risk 
reduction for a moderate or severe exacerbation, whereas 
MF/F 200/10 µg had a 48.0% relative risk reduction for a 
moderate or severe exacerbation. MF/F 400/10 µg showed 
a statistically significant reduction in moderate and severe 
exacerbations compared not only to placebo but also to MF 
and F alone. This occurred despite the fact that the treat-
ment period was only 6 months, a time period over which, 
historically, it has been difficult to show significant effects 
on exacerbations with pharmacotherapy.
All four active treatments were well tolerated, and there 
were no notable differences in the occurrence or nature of 
AEs reported for MF/F 400/10 µg compared with MF 400 µg 
or F 10 µg alone. The incidence of treatment-emergent 
pneumonia was low, and no occurrences of pneumonia 
were considered by investigators to be treatment-related. 
Regarding systemic safety, effects on HPA axis suppression 
were quite modest, and no significant demonstrable adverse 
effects on the cardiovascular system, bone mineral density, 
lenticular opacities, or intra-ocular pressure occurred in 
the subpopulation studied. Longer trials would be needed 
to exclude any long-term effects of MF/F on BMD and 
ocular safety.
Table 4 Treatment-emergent adverse events in $2% of subjects in any active treatment group over the safety extension
Number of subjects (%)
MF/F 400/10 μg BID 
(n = 145)
MF/F 200/10 μg BID 
(n = 153)
MF 400 μg BID 
(n = 149)
F 10 μg BID 
(n = 148)
Headache 1 (0.7) 6 (3.9) 3 (2.0) 2 (1.4)
Upper respiratory tract infection 9 (6.2) 4 (2.6) 2 (1.3) 5 (3.4)
Nasopharyngitis 5 (3.4) 5 (3.3) 7 (4.7) 2 (1.4)
Bronchitis 0 2 (1.3) 1 (0.7) 3 (2.0)
Influenza 0 2 (1.3) 3 (2.0) 2 (1.4)
COPD* 2 (1.4) 4 (2.6) 5 (3.4) 3 (2.0)
Hypertension 0 2 (1.3) 3 (2.0) 0
Back pain 2 (1.4) 0 1 (0.7) 3 (2.0)
Arthralgia 3 (2.1) 4 (2.6) 0 0
Lenticular opacities 3 (2.1) 3 (2.0) 0 1 (0.7)
Note: *If COPD exacerbation met criteria for a severe adverse event (eg, was life-threatening, required hospitalization, or prolonged hospitalization), it was recorded as 
an adverse event.
Abbreviations: BID, twice daily; COPD, chronic obstructive pulmonary disease; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose 
combination formulation.
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Smoking is the greatest risk factor for COPD, with 
environmental and occupational exposures contributing as 
well. Smoking cessation and avoidance of other exposures 
is an integral part of COPD prevention and treatment. In the 
present study, the MF/F 400/10 µg group had the greatest 
proportion of current smokers, as well as a pack-year smoking 
history that was up to 36% greater than the other treatment 
groups. The ANCOVA model adjusted for this imbalance by 
including smoking as a covariate.
The efficacy of an inhaled medication is influenced by 
factors that include pharmacodynamic properties, particle 
size, and lung deposition of the drug(s) being  administered; 
the type of inhaler being used (ie, MDI or DPI); as well as 
the patient’s inhaler technique.31 With HFA-type MDIs, 
the patient inhales deeply and slowly through the mouth 
after device actuation to draw medication into the lungs. 
Proper hand-breath coordination of device actuation and 
inhalation is necessary to ensure that a sufficient dose of 
medication is inhaled, and some patients may need to use a 
spacer or  holding chamber to achieve optimal drug delivery. 
No spacers or holding chambers were utilized in this study. 
In  contrast, drug delivery with a DPI is breath-actuated. 
The patient places the inhaler in his or her mouth and takes 
a rapid, deep breath to inhale the medication into the lungs. 
Deficiencies in a patient’s inhaler technique and treatment 
adherence can lead to suboptimal outcomes, and thus 
 appropriate device selection and attention to patients’ inhaler 
acceptance and technique are essential for the  successful 
management of COPD.32,33
Conclusion
Treatment with MF/F was found to be effective for patients 
with moderate-to-very severe COPD, based on improvement 
in lung function and health status, as well as reduction in 
COPD exacerbations. The MF component was shown to 
contribute to the combination, based on AM pre-dose (trough) 
FEV
1
 improvement with MF/F versus F when considering 
observed cases across all time points. The F component was 
shown to significantly contribute to the combination, based 
on FEV
1
 AUC
0–12 h
 improvement with MF/F versus MF, with 
improvements in FEV
1
 that occur rapidly and are sustained 
over time. The two MF/F combination doses evaluated in 
this study were well tolerated. Very low rates of pneumonia 
occurred in all treatment groups.
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